Slide 1: Q4 2022 Results Presentation
Q4 2022 Results Presentation Dietmar Siemssen, CEO Dr. Bernd Metzner, CFO Duesseldorf, February 23, 2023
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: 2022: A Profitable Growth Company
2022: A Profitable Growth Company 3 23-Feb-2023 Gerresheimer AG - Q4 2022 Results Presentation
Slide 4: Consistent Execution of our Growth Strategy
Consistent Execution of our Growth Strategy Focus for 2022: Accelerate – Execute – Innovate FY 2022 - Key Priorities What we achieved in FY 2022: — Another record year driven by High Value Solutions, Accelerate execution of growth projects as well as strong pricing power — Strong order intake transl
Slide 5: Sustainable Value Creation Proven by Double-Digit Growth
Sustainable Value Creation Proven by Double-Digit Growth Strategic Focus & Achievements in FY 2022 Growth: formula G: Customer centricity: Further increasing Continuously expand Proven global solution & momentum – the portfolio system provider for pharma, double-digit growth with High Value Solution
Slide 6: Gerresheimer is a Profitable Growth Company
Gerresheimer is a Profitable Growth Company 2015 2015 2019 2020 2021 2022 6 23-Feb-2023 Gerresheimer AG - Q4 2022 Results Presentation
Slide 7: Consistent Execution of our Strategy & Delivery on Financial Targets
Consistent Execution of our Strategy & Delivery on Financial Targets Key Take-Aways FY 2022: Growth Further Accelerated Strong Performance: High Value Solutions: Taking sustainable 19% revenue growth profitable growth Revenue growth Adj. EBITDA growth: – to the next level +16.2% (FXN) +10.2% (FXN) N
Slide 8: Strategic Partner of Choice for Global Pharma and Biotech Solutions
Strategic Partner of Choice for Global Pharma and Biotech Solutions Continuous Expansion of High Value Solutions Enables Mix Shift & Margin Expansion Bring the Drug to the Patient Bring the Drug into the Patient Digital Ecosystem Containment Drug Devices & Digital Therapy Solutions Delivery Systems
Slide 9: Attractive Markets Served With a Unique Portfolio
Attractive Markets Served With a Unique Portfolio Investing Into the Right Areas: High Value Solutions, Biologics & Injectables BioPharma & Diagnostics Beauty & Cosmetics Biologics & Injectables Diversified Therapies in: End Markets1 Diagnostics Masstige Prestige Antibodies & Cell & Gene Vaccines an
Slide 10: Gx Biological Solutions - Unique Growth Opportunities
Gx® Biological Solutions - Unique Growth Opportunities Global go-to-partner for syringes, vials, cartridges and devices Long term expertise in core technologies Biologics (as part of HVS) ▪ Shift from small molecules towards biologicals and % of Total Sales new modalities ▪ Primary packaging contain
Slide 11: Holistic Support Along the Entire Drug Development Process
Holistic Support Along the Entire Drug Development Process Advanced Solutions for Biotechs Secure Early Stage Involvement in Drug Development Phase Preclinical Clinical Approval to Life cycle testing testing launch management Small scale samples Final packaging Product support to even ease initial d
Slide 12: Innovating for a Better Life: Fighting Obesity
Innovating for a Better Life: Fighting Obesity GLP-1 is one Example of the Increasing Demand in Biological Solutions Chronic Obesity: $50 billion Market Potential Source: Morgan Stanley Research, July 14, 2022 12 23-Feb-2023 Gerresheimer AG - Q4 2022 Results Presentation
Slide 13: Confirming our Leading Position in Syringes and Contract Manufacturing
Confirming our Leading Position in Both Syringes and Contract Manufacturing Large “Eagle“ Contracts: Pushed by Diabetes/GLP-1 and Obesity Business Significant large business Attractive risk/return opportunities lead to profile with limited expansion of global downside risk footprint – also in syring
Slide 14: Gerresheimer is a Profitable Growth Company
Delivering Double-Digit Organic Growth – Profitably and Sustainably Consistent Execution of our Strategy & Delivery on Financial Targets Gerresheimer is a Profitable Growth Company ▪ FY 2022 has been another proof point of consistent execution and delivery ▪ Stable through the storm: strategy based
Slide 15: Strong Q4 & FY 2022
Strong Q4 & FY 2022 Dr. Bernd Metzner (CFO)
Slide 16: Profitable Growth: Another Double-Digit Quarter
Profitable Growth: Another Double-Digit Quarter Operational View on KPIs in Q4 2022 organic growth yoy Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) 15.9% 11.9% 10.7% 529 112 436 95 1.49 1.31 501 106 432 95 1.45 1.31 Q4 2021 Q4 2022 Q4 2021 Q4 2022 Q4 2021 Q4 2022 Reported Organic (ad
Slide 17: Consistently Proving Strong Pricing Power
Consistently Proving Strong Pricing Power Q4 2022 Revenue Growth Reconciliation Focus on Q4 2022: Focus FY 2022: ~16% ~16% ~0% ~1% ~6% ~6% ~10% ~9% Q4 2022 Contractual Sustainable Q4 2022 FY 2022 Contractual Sustainable FY 2022 org. revenue growth pass-through price increases revenue growth org. rev
Slide 18: Strong Divisional Performance in Q4 2022
Strong Divisional Performance in Q4 2022 Q4 2022: Divisional Performance and Highlights Organic yoy & margin In EUR m Revenues Adj. EBITDA Double-Digit Organic Growth +13.8% +15.2% 288 81 ▪ Strong growth based on volume and price 241 67 P&D ▪ Organic growth in Adj. EBITDA of 15.2% outperforming the
Slide 19: Excellent FCF Performance
Excellent FCF Performance Cash Flow and Financial Debt In EUR m Q4 2022 Q4 2021 Change Comments Adjusted EBITDA 112.0 95.4 16.6 Earnings significantly increased Change in net working capital 48.5 63.6 -15.1 Net interest paid -14.2 -11.8 -2.4 Net taxes paid -7.3 -10.9 3.6 Other 3.0 -2.2 5.2 Cash flow
Slide 20: Reconciliation FY 2022
Reconciliation FY 2022 Reported and Adjusted Financials Org. growth FY 2022 FY 2021 YoY1 In EUR m Comments Reported Adjustment Adjusted Adjusted Adjusted Revenues 1,817.1 1,817.1 1,498.0 16.2% Adjustments mainly due to one-time payment for EBITDA 335.6 18.6 354.2 306.3 10.2% inflation compensation t
Slide 21: Outlook
Outlook Dietmar Siemssen (CEO)
Slide 22: Double-Digit Organic Revenue Growth in 2023
Double-Digit Organic Revenue Growth in 2023 Key Contributors to Growth ≥ +10% Revenue 2022 High Value Solutions Medical Devices Further growth initatives Revenue 2023 Successful strategy implementation delivers sustainable profitable growth 22 23-Feb-2023 Gerresheimer AG - Q4 2022 Results Presentati
Slide 23: Outlook and Guidance
Outlook and Guidance FY 2023 and Mid-Term Guidance Group level guidance (FXN, organic) focused on three key drivers of shareholder value Revenue Growth Adjusted EBITDA Adjusted EPS (in %) ≥ 10% Low FY 2023 ≥ 10% (Adj. EBITDA single-digit growth) growth 23-25% Mid-term ≥ 10% (Adj. EBITDA ≥ 10% margin
Slide 24: Maintain Profitable Growth Momentum
Maintain Profitable Growth Momentum Outlook for Q1 2023 ▪ Good start to the year: Q1 23 confirms we are on track to deliver on profitable growth Q1 2023 ▪ We expect double-digit organic growth in revenues and adj. EBITDA. Adj. EBITDA margin is expected to improve year-on-year 24 23-Feb-2023 Gerreshe
Slide 25: Appendix
Appendix
Slide 26: Financial Calendar
Financial Calendar Publication 1st Annual General Publication 2nd Publication 3rd Quarter Results 2023 Meeting 2023 Quarter Results 2023 Quarter Results 2023 April June July October 6th, 2023 7th, 2023 6th, 2023 5th, 2023 26 23-Feb-2023 Gerresheimer AG - Q4 2022 Results Presentation
Slide 27: Q4 Revenue & Organic Growth Reconciliation
Q4 Revenue & Organic Growth Reconciliation (1 of 4) in EUR m organic growth 27.7 528.7 +15.9% 501.0 1.1 -0.5 35.0 33.1 +18.1% 436.1 432.2 -3.9 +13.8% Revenue Q4 2021 FX Revenue Q4 P&D PPG GAT HQ, Cons. Revenue Q4 FX Revenue Q4 2022 2021 (FXN) 2022 (FXN) 27 23-Feb-2023 Gerresheimer AG - Q4 2022 Resul
Slide 28: Q4 Adj. EBITDA & Organic Growth Reconciliation
Q4 Adj. EBITDA & Organic Growth Reconciliation (2 of 4) in EUR m organic growth & margin 5.9 112.0 +11.9% 106.1 0.8 0.5 -0.1 -0.3% 10.1 95.4 94.8 -0.6 +15.2% 21.9% 21.2% Adj. EBITDA FX Adj. EBITDA P&D PPG GAT HQ, Cons. Adj. EBITDA FX Adj. EBITDA Q4 2021 Q4 2021 (FXN) Q4 2022 (FXN) Q4 2022 28 23-Feb-
Slide 29: FY 2022 Revenue & Organic Growth Reconciliation
FY 2022 Revenue & Organic Growth Reconciliation (3 of 4) in EUR m organic growth 79.0 1,817.1 +16.2% 1,738.1 5.0 -5.2 143.4 99.2 +20.8% 1,498.0 1,495.6 -2.4 +12.3% Revenue FY 2021 FX Revenue FY P&D PPG GAT HQ, Cons. Revenue FY FX Revenue FY 2022 2021 (FXN) 2022 (FXN) 29 23-Feb-2023 Gerresheimer AG -
Slide 30: FY 2022 Adj. EBITDA & Organic Growth Reconciliation
FY 2022 Adj. EBITDA & Organic Growth Reconciliation (4 of 4) in EUR m organic growth & margin 15.7 354.2 +10.2% 338.4 3.0 -2.3 12.8 +8.9% 17.8 306.3 307.1 0.8 +8.8% 20.5% 19.5% Adj. EBITDA FX Adj. EBITDA P&D PPG GAT HQ, Cons. Adj. EBITDA FX Adj. EBITDA FY 2021 FY 2021 (FXN) FY 2022 (FXN) FY 2022 30
Slide 31: Strong Investments Into Profitable Growth
Strong Investments Into Profitable Growth Cash Flow and Financial Debt In EUR m FY 2022 FY 2021 Change Comments Adjusted EBITDA 354.2 306.3 47.8 Earnings significantly increased Higher NWC due to strong topline growth as well as safety Change in net working capital -47.5 9.3 -56.8 stock. Net interes
Slide 32: Reconciliation Q4 2022
Reconciliation Q4 2022 Reported and Adjusted Financials Q4 2022 Q4 2021 Org. growth YoY1 Comments In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 528.7 528.7 436.1 15.9% Adjustments mainly due to one-time payment for EBITDA 102.9 9.1 112.0 95.4 11.9% inflation compensation to employ
Slide 33: Financial Headroom
Financial Headroom Net Financial Debt & Adjusted EBITDA Leverage Net Financial Debt according to credit agreement in force Maturity Profile In EUR m In EUR m 1,050 Net Financial Debt 961 Promissory loans (In EUR m)1 3.2 Revolving credit facility (RCF) 3.0 Adj. EBITDA leverage (x) Nov-22 Nov-21 In EU
Slide 34: serresheimer
serresheimer innovating for a better life